FDA Approves Circassia’s COPD Drug

April 25, 2019

The FDA has approved Circassia’s Duaklir for treatment of chronic obstructive pulmonary disease (COPD).

The combination product uses the Pressair inhaler to deliver the dry powder aclidinium bromide/formoterol, relaxing the airway muscles to allow the patient to breath more easily.

Circassia says it plans to launch the product on the U.S. market in the coming months.

View today's stories